final exam data article

Endothelins and Receptors: Vital regulators of cardiovascular functions, maintaining vascular tone and homeostasis.
- Types: Three endothelin peptides (ET-1, ET-2, ET-3) activate receptors ETA and ETB.
- Sequence Homology: Human ETA and ETB share 63% sequence homology but differ in ligand affinity and function.
Receptor Function:
- ETA: Binds ET-1 and ET-2 with preference; induces vasoconstriction.
- ETB: Equal affinity for all isoforms; primarily induces vasorelaxation via nitric oxide and helps clear ET-1.
Therapeutic Strategies: Targeting ETRs with selective antagonists for treating diseases like pulmonary arterial hypertension (PAH).

Cryo-Electron Microscopy (cryo-EM): Used to elucidate structures of ETA in complex with various antagonists (macitentan, ambrisentan, zibotentan).
- Methods: Development of an optimized strategy to determine inactive ETA structure, overcoming challenges in G protein-coupled receptor (GPCR) studies.
Key Findings: Identification of key residues conferring antagonist selectivity, elucidation of binding modes, and understanding activation mechanisms of ETA and ETB receptors.

Affinity: High affinity (IC50: 1.3 nM for ETA; 14.5 μM for ETB).
Interactions:
- Sulfonamide forms hydrogen bonds with R3266.55 and ionic interactions with K1663.33, K2555.38.
- Bromophenyl group engages in hydrophobic interactions with residues in TM3, TM5, and TM6.

Chemical Structure: Propionic acid derivative, smaller than macitentan.
Mechanism: Forms ionic interactions with K1663.33 and R3266.55; exhibits robust hydrogen bonding and snug fit with hydrophobic subpockets.

Selectivity: Exhibits structure-based selectivity through interactions with residues F1613.28 and Y1292.53 in ETA compared to ETB.
Binding Features: Engages in significant hydrophobic interactions and polar contacts that stabilize its binding.

Binding Pocket Structure: Differences in the compactness of binding pockets, affected by F1613.28 in ETA and V1773.28 in ETB, play a role in selectivity.
Active vs. Inactive Conformations: Structural shifts upon agonist binding (ET-1) vs. antagonist binding (macitentan) revealing distinct activation pathways in ETA and ETB.

Structural Insights from ET-1 Binding:
- Movement of transmembrane helices and key residues facilitating GPCR activation.
- Specific motifs within ETA critical for maintaining receptor function upon ligand binding.

Antibody Fab301: Stabilizes ETA structures and provides antagonistic effects; crucial for understanding antibody-receptor interfaces.
Key Residues: R232ECL2 and G233ECL2 critical for Fab301 binding; mutagenesis studies analyzed for their roles in function.

Theoretical Framework: Insights into ETR selectivity and binding mechanisms aid in rational design of antagonists.
Future Directions: Structural templates outlined for designing selective antibodies and small-molecule drugs aimed at selective therapeutic interventions.

Research & Development: Supported by various Chinese scientific programs focusing on advancing vascular therapies and related research.

Overview of Endothelin Receptors and Antagonist Selectivity

What are Endothelins? Endothelins are important substances in our body that help control how blood flows by managing the size of our blood vessels.
Types of Endothelins: There are three types: ET-1, ET-2, and ET-3. They work on special places called receptors, named ETA and ETB.
How do they work? The ETA receptor likes ET-1 and ET-2 and makes blood vessels squeeze tighter, while the ETB receptor can work with all three types and usually helps relax the blood vessels.
Why is it important? Scientists are developing medicines that can block these receptors to help with diseases like pulmonary arterial hypertension, which makes it hard for blood to flow properly.

How Scientists Study These Receptors

Using Special Tools: Scientists use high-tech tools like Cryo-Electron Microscopy to see how the ETA receptor looks when different medicines attach to it.

Different Medicines and How They Work:

Macitentan: This medicine sticks well to the ETA receptor and helps it work better.
Ambrisentan: Smaller than macitentan, but also fits nicely into the receptor.
Zibotentan: This one is special because it sticks to certain parts of the receptor to work better than others.

Why Are They Different?

The shape of the place where the medicine attaches can change how well different medicines work with the receptors.
When the receptor is excited by a substance like ET-1, it acts differently than when a medicine like macitentan is attached.

What About Antibodies?

Researchers are also looking at antibodies (which help our body fight things that are not good for us) to see how they can help block these receptors too.

Final Thoughts

By understanding how these receptors work and how medicines attach to them, scientists can create better medicines for people who need help with their blood flow issues.